PBAC post-market reviews of chronic obstructive pulmonary disease medicines and ezetimibe

5 August 2016 - The public submission process is now closed. ...

Read more →

Praluent recommended for reimbursement by CADTH

20 July 2016 - CADTH has recommended that alirocumab (Praluent) be reimbursed in Canada. ...

Read more →

NICE issues draft guidance on alirocumab for lipid disorder

8 February 2016 - NICE has published draft guidance not recommending alirocumab (Praluent, Sanofi/Regeneron) as an option for people with high ...

Read more →

PBAC rebukes Amgen for lodging early submission for Repatha under TGA-PBAC parallel process

6 January 2016 - The PBAC noted that the intent of the submission was to initiate a dialogue rather than ...

Read more →

NICE issues revised draft guidance on ezetimibe for hypercholesterolaemia

24 December 2015 - NICE is reviewing its guidance on ezetimibe (Ezetrol, MSD) for adults with primary (heterozygous-familial and non-familial) hypercholesterolaemia. ...

Read more →

Evolocumab: no hint of added clinical benefit according the IQWiG in Germany

15 December 2015 - The dossier contained no suitable data for hypercholesterolaemia or for mixed dyslipidaemia. ...

Read more →

Evolocumab: no evidence of additional clinical benefits says IQWiG

15 December 2015 - The dossier did not contain appropriate data for patients with hypercholesterolaemia nor for mixed dyslipidaemia. ...

Read more →